Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan in children and adolescents with autism spectrum disorder
2020-003173-22Phase 2
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Balovaptan with Placebo (2 arms). Primary endpoint: Change from baseline in Vineland-II Adaptive Behavior Scales Two Domain Composite score at Week 24.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2020-003173-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003173-22.